Jyong Biotech Ltd. (Revived IPO) MENS 深 沪
等待开盘 09-29 09:30:00 美东时间
59.74
+0.490
+0.83%
华盛通- 最 高60.575
- 今 开58.50
- 成交量 52.51万股
- 最 低 57.00
- 昨 收 59.25
- 总市值 45.42亿
- 52周最高 67.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.0101
- 委 比 0.00%
- 总股本 7602.77万
- 历史最高 67.00
- 量 比 1.12
- 振 幅 6.03%
- 历史最低 6.0101
- 每 手 1
- 风险率 20.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei
New Taipei City, Taiwan, September 18, 2025 – Jyong Biotech Ltd. announced that its chairwoman and CEO, Fu Feng Kuo, will speak at the 2025 Global Business Forum on September 19. The event, organized by the Taiwanese Chambers of Commerce of North America, aims to facilitate US-Taiwan biotech collaboration. Kuo will discuss aligning Taiwan's biotech and medical industries with global trends. The forum will focus on innovative drug development, cro...
09-18 12:30
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
Jyong Biotech Ltd., a Taiwanese biotechnology company focused on developing plant-derived drugs for urinary system diseases, has successfully completed patient enrollment in its Phase II clinical trial for MCS-8, an investigational prostate cancer prevention drug, with over 700 high-risk participants recruited across 20 hospitals in Taiwan. The trial, conducted during the COVID-19 pandemic, has exceeded expectations, highlighting the company's pr...
09-16 12:18
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
Jyong Biotech Ltd., a Taiwanese biotech company, presented results from Phase III clinical trials of BOTRESO® for benign prostatic hyperplasia (BPH) at the 22nd Urological Association of Asia Congress. The trials showed significant improvement in lower urinary tract symptoms in Asian and Taiwanese subgroups, with long-term safety confirmed. BOTRESO® is the first Taiwanese-developed oral botanical drug to reach Phase III in the U.S. The company al...
08-22 13:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
08-12 01:06
美股周涨跌榜 | 本周涨超137%！次新股MENS上市累涨超500%；以太坊概念股BMNR周涨超62%
本周涨超137%！次新股MENS上市已累涨超500%；以太坊概念股BMNR周涨超62%，特朗普新政允许401K账户投资加密货币等其他另类投资>>
08-09 10:07
美股周涨跌榜 | 上市首周受热捧，Figma周涨近270%；乳腺癌药物实验效果积极，CELC周涨近190%
上市首周受热捧，Figma周涨近270%；乳腺癌药物实验效果积极，CELC周涨近190%；FDA人事变动或缓解监管压力，SRPT周涨超33%>>
08-02 10:39
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Soligenix (NASDAQ:SNGX) shares rose 192.0% to $3.65 during Thursday's ...
08-01 01:08
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
Jyong Biotech Ltd., a Taiwan-based biotech company specializing in plant-derived drugs for urinary system diseases, completed its Nasdaq IPO and participated in BIO 2025, showcasing its flagship product MCS-2 targeting the BPH market. With global aging and rising obesity driving demand, the BPH market is projected to grow from $4.1B in 2020 to $9.8B by 2026. The company aims to leverage its plant-based drug innovation and global partnerships to e...
07-22 14:40
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Shares of Thumzup Media Corporation (NASDAQ:TZUP) rose sharply in today's pre-m...
07-01 17:23
